NC
CLPT icon

nVerses Capital’s ClearPoint Neuro CLPT Stock Holding History

nVerses Capital’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,668
Closed -$170K – 338
2026
Q1 		$170K Buy
+18,668
New +$236K 0.15% 288

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CFML
COMPASS FINANCIAL MANAGEMENT LLC Tampa, Florida $829M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

nVerses Capital's CLPT Position: Q2 2026 in Review

nVerses Capital sold out of ClearPoint Neuro (CLPT) in Q2 2026, closing a stake of 18,668 shares — an estimated $170K sold.

nVerses Capital first reported a position in CLPT in Q1 2026 and held it in 1 quarter. The position peaked at $170K in Q1 2026. 94 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • nVerses Capital reported no remaining ClearPoint Neuro position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 18,668 ClearPoint Neuro shares in Q2 2026, an estimated $170K.
  • nVerses Capital first reported a position in ClearPoint Neuro in Q1 2026 and held it in 1 quarter.
  • nVerses Capital's ClearPoint Neuro position peaked at $170K in Q1 2026.
  • 94 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.